Early profiles of clinical evolution after intravenous thrombolysis in an unselected stroke population.

Fiche du document

Auteurs
Discipline
Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/jnnp.2009.185363

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/19850577

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1468-330X

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_42AA13E2190C3

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/restrictedAccess , Restricted: indefinite embargo , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Adult; Aged; Aged, 80 and over; Brain Edema/diagnosis; Brain Edema/diagnostic imaging; Brain Edema/mortality; Cerebral Angiography; Cerebral Infarction/diagnosis; Cerebral Infarction/diagnostic imaging; Cerebral Infarction/drug therapy; Cerebral Infarction/mortality; Disease Progression; Female; Fibrinolytic Agents/administration & dosage; Fibrinolytic Agents/adverse effects; Humans; Intracranial Hemorrhages/chemically induced; Intracranial Hemorrhages/diagnosis; Intracranial Hemorrhages/diagnostic imaging; Intracranial Hemorrhages/mortality; Intracranial Hypertension/diagnosis; Intracranial Hypertension/diagnostic imaging; Intracranial Hypertension/mortality; Male; Middle Aged; Neurologic Examination/drug effects; Prognosis; Recurrence; Sex Factors; Survival Rate; Thrombolytic Therapy; Tissue Plasminogen Activator/administration & dosage; Tissue Plasminogen Activator/adverse effects; Tomography, Spiral Computed; Treatment Outcome; Young Adult

Sujets proches En

Tsʻeu Tzʻu Ci Tse

Citer ce document

M.G. Delgado et al., « Early profiles of clinical evolution after intravenous thrombolysis in an unselected stroke population. », Serveur académique Lausannois, ID : 10.1136/jnnp.2009.185363

Métriques

Partage / Export

Résumé 0

Intravenous recombinant tissular plasminogen activator (rt-PA) is the only approved pharmacological treatment for acute ischaemic stroke. The authors aimed to analyse potential causes of the variable effect on early course and late outcome. 136 patients (42% women, 58% men) treated with intravenous rt-PA within 3 h of stroke onset in an acute stroke unit over a 3-year period, were included. Early clinical profiles of evolution at 48 h were divided into clinical improvement (CI) (decrease >4 points in the National Institute of Health Stroke Scale (NIHSS)); clinical worsening (CW) (increase >4 points NIHSS); clinical worsening after initial improvement (CWFI) (variations of >4 points in the NIHSS). Patients with clinical stability (no NIHSS modification or

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Sur les mêmes disciplines

Exporter en